Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Recruiting 1Active not recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 5Breast 5Head & Neck 3Genitourinary 2Gastrointestinal 2Thoracic 1

Conditions

Breast Neoplasms 9Colorectal Neoplasms 6Ovarian Neoplasms 4Triple Negative Breast Neoplasms 3Stomach Neoplasms 3Prostatic Neoplasms 3Endometrial Neoplasms 3Carcinoma, Non-Small-Cell Lung 3Uterine Cervical Neoplasms 2Small Cell Lung Carcinoma 2Pancreatic Neoplasms 2Neoplasm Metastasis 2Uterine Neoplasms 1Urologic Neoplasms 1Urinary Bladder Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Spinocerebellar Degenerations 1Sarcoma 1Lung Neoplasms 1Liposarcoma 1Esophageal Squamous Cell Carcinoma 1Digestive System Neoplasms 1Colonic Neoplasms 1Cholangiocarcinoma 1Carcinosarcoma 1Carcinoma, Ovarian Epithelial 1Carcinoma, Lobular 1Biliary Tract Neoplasms 1Adenocarcinoma of Lung 1Adenocarcinoma Of Esophagus 1

Interventions

pembrolizumab 35Nivolumab 13Cyclophosphamide 11fludarabine 9aldesleukin 9atezolizumab 7Magnetic Resonance Spectroscopy 7Carboplatin 7Specimen Handling 6Ipilimumab 6Early Intervention, Educational 6Cisplatin 6Trastuzumab 5Paclitaxel 5Methods 5Biopsy 5Bevacizumab 5durvalumab 4Vaccines 4Surveys and Questionnaires 4Radiotherapy 4Papillomavirus Vaccines 4Interleukin-2 4Docetaxel 4tisotumab vedotin 3spartalizumab 3fludarabine phosphate 3cemiplimab 3aflibercept 3Tomography, X-Ray Computed 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Uterine Cervical Neoplasms × Fulvestrant × Gastrointestinal × Clear all
NCT07109726 2026-05-22

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

Terremoto Biosciences Inc.

Phase 1/2 Recruiting
205 enrolled
BreastGastrointestinalGynecologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Esophageal Squamous Cell Carcinoma, Breast Neoplasms, Uterine Cervical Neoplasms, Ovarian Neoplasms, Endometrial Neoplasms

NCT04579380 2025-12-19

Basket Study of Tucatinib and Trastuzumab in Solid Tumors With HER2 Alterations

Seagen Inc.

Phase 2 Active not recruiting
217 enrolled 19 charts
BreastGastrointestinalGenitourinaryGynecologicThoracic

Biliary Tract Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Urologic Neoplasms, Uterine Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡